awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q51742255-0FE8A370-F7DF-4B29-B227-2CDFDD667856
Q51742255-0FE8A370-F7DF-4B29-B227-2CDFDD667856
BestRank
Statement
http://www.wikidata.org/entity/statement/Q51742255-0FE8A370-F7DF-4B29-B227-2CDFDD667856
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
P2860
Q51742255-0FE8A370-F7DF-4B29-B227-2CDFDD667856
BestRank
Statement
http://www.wikidata.org/entity/statement/Q51742255-0FE8A370-F7DF-4B29-B227-2CDFDD667856
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
356da189c145294b7c4cbd5b8d82b126045b63cf
P2860
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.